secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001193125-22-207816
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio discontinues NUV-422 program due to uveitis safety; cuts 35% of staff
--------------------------------------------------------------------------------

- Discontinued NUV-422 clinical program after FDA partial clinical hold due to unpredictable uveitis safety signal.
- Workforce reduction of ~30 employees (35%) expected to save ~$11.8M annually; restructuring charges of ~$5.8M in Q3 2022.
- Cash, cash equivalents and marketable securities of ~$703.8M as of June 30, 2022; cash runway extended through 2028.
- Prioritizing NUV-868 (BD2-selective BET inhibitor) and novel small molecule DDC platform for future development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522207816/0001193125-22-207816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522207816/d379263d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-207816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer